share_log

石藥集團：自願公告 - 雙特異性融合蛋白藥物JMT106獲美國臨床試驗批准

CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

香港交易所 ·  Jan 15 16:48
Summary by Futu AI
石藥集團有限公司宣佈，其開發的雙特異性融合蛋白藥物JMT106獲得美國食品藥品監督管理局(FDA)批准進行臨床試驗。該藥物主要針對GPC3陽性的實體瘤，具有針對性殺傷腫瘤細胞和激活腫瘤微環境免疫調控作用。臨床前研究顯示JMT106在多種惡性腫瘤模型中表現出顯著的抗腫瘤效果和良好的安全性，被認為具有高臨床開發價值。此次臨床試驗批准為石藥集團在腫瘤治療領域的一大進展，並於2024年1月15日由公司主席蔡東晨宣布。
石藥集團有限公司宣佈，其開發的雙特異性融合蛋白藥物JMT106獲得美國食品藥品監督管理局(FDA)批准進行臨床試驗。該藥物主要針對GPC3陽性的實體瘤，具有針對性殺傷腫瘤細胞和激活腫瘤微環境免疫調控作用。臨床前研究顯示JMT106在多種惡性腫瘤模型中表現出顯著的抗腫瘤效果和良好的安全性，被認為具有高臨床開發價值。此次臨床試驗批准為石藥集團在腫瘤治療領域的一大進展，並於2024年1月15日由公司主席蔡東晨宣布。
PETROLEUM GROUP CO., LTD. ANNOUNCED THAT ITS DEVELOPED BI-SPECIFIC FUSION PROTEIN DRUG JMT106 HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CLINICAL TRIALS. The drug is primarily directed against GPC3-positive solid tumors, with targeted killing of tumor cells and activating tumor microenvironmental immunomodulation. Preclinical studies show that JMT106 shows significant antitumor efficacy and good safety in multiple malignant tumor models and is considered to have high clinical development value. The approval of this clinical trial marks a major advance in the field of oncology therapy for the Petrochemical Group and was announced on January 15, 2024 by the Chairman of the Company, Tung Chen Cai.
PETROLEUM GROUP CO., LTD. ANNOUNCED THAT ITS DEVELOPED BI-SPECIFIC FUSION PROTEIN DRUG JMT106 HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CLINICAL TRIALS. The drug is primarily directed against GPC3-positive solid tumors, with targeted killing of tumor cells and activating tumor microenvironmental immunomodulation. Preclinical studies show that JMT106 shows significant antitumor efficacy and good safety in multiple malignant tumor models and is considered to have high clinical development value. The approval of this clinical trial marks a major advance in the field of oncology therapy for the Petrochemical Group and was announced on January 15, 2024 by the Chairman of the Company, Tung Chen Cai.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.